• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left
ventricular hypertrophy not solely explained by abnormal loading conditions. Despite its rare …

Cardiomyopathies (CMPs) are myocardial diseases in which the heart muscle is structurally
and functionally abnormal in the absence of coronary artery disease, hypertension, valvular …

Background Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by
mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the …

Cardiomyopathies are a heterogeneous collection of diseases that have in common primary
functional and structural abnormalities of the heart muscle, often genetically determined. The …

Cardiomyopathy (CMP) is a heritable disorder. Over 50% of cases are gene-elusive on
clinical gene panel testing. The contribution of variants in non-coding DNA elements that …

Heart failure with preserved ejection fraction (HFpEF) is a major driver of cardiac morbidity
and mortality in developed countries, due to ageing populations and the increasing …

Despite significant progress in cardiovascular pharmacotherapy and interventional
strategies, cardiovascular disease (CVD), in particular ischaemic heart disease, remains the …

Restrictive cardiomyopathy (RCM) is the least frequent phenotype among pediatric heart
muscle diseases, representing only 2.5–3% of all cardiomyopathies diagnosed during …

BACKGROUND: The cause of hypertrophic cardiomyopathy (HCM) in the young is highly
varied. Ventricular preexcitation (preexcitation) is well recognized, yet little is known about …